Trial Profile
An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Drug (DMARD) Therapy in Biologic-Naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Golimumab (Primary) ; Disease-modifying antirheumatics
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms GO-MORE
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.; Schering-Plough; Schering-Plough Research Institute
- 19 Jun 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 06 Jun 2017 Results (n=98) of a subgroup analysis from the Italian cohort of this study, published in the Clinical and Experimental Rheumatology.
- 25 Apr 2016 Results published in the Rheumatology